The transition of Value Research Online has been postponed to take care of some user concerns.
You are welcome to try out the new site at

The small cap maven

Specialising in mid and small caps, R Janakiraman talks to all stakeholders before investing in a company

  • TweetTweet
  • LinkedinLinkedin
  • FacebookShare

The small cap maven

R Janakiraman, VP and Portfolio Manager - Equities, Franklin Templeton India is a mid and small-cap specialist. He manages Franklin India Smaller Companies and Prima Funds. While researching potential investments, Janakiraman talks to all stake holders which include companies, its suppliers and customers, competitors and even retired professionals. According to Janakiraman, the dominant player in an industry often creates value, while other me-too stocks of the same industry just join the ride up.

Subscribe to the Value Research Insight newsletter

What he's buying: Idea, HPCL, Info Edge
Janakiraman has bought mobile operator Idea Cellular and PSU refiner HPCL. The public sector refiner was acquired by the upstream oil major, Oil and Natural Gas Corp (ONGC). In the mid-cap space, Janakiraman loaded up on Info Edge. The company is selling stake in its food delivery firm Zomato Media Pvt Ltd to Chinese online giant Alibaba Group for $50 million.

What he sold: IndusInd Bank, technology stocks
Janakiraman's biggest stake cut was in IndusInd bank, which is trading at close to 10-year highs and is still expensive at a price to book of 4.6x. He also reduced stakes in technology companies, completely exiting Oracle Financial Services and pruning position in Mindtree and Cyient.

What he's loading up on: Idea Cellular
Janakiraman loaded up on Idea Cellular. He bought more than Rs 420 crore worth of shares of India's third-largest telecom operator. Idea is going to merge with Vodafone, the country's second largest. The Idea-Voda combine will overtake Airtel and become number one in a now four-player industry.

An interesting pick: Colgate-Palmolive
Colgate trades at 45 times earnings. The stock has not gone anywhere in the last three years and the company has lost around 4 per cent market share, mostly to upstart Patanjali. Colgate's counter attack with its new launches of Ayurveda products has helped arrest further market share loss. The valuations though are eye-watering.

Here's the link to the other stories in this series.

It's time to start building your stock portfolio with great stocks at low valuations.

Our equity analyst team has sifted through hundreds of companies and selected a short list of stocks that you should invest in. This list now has 37 stocks on it. Thousands of our members are using stagnant equity markets to buy great stocks at low prices.

Membership is currently available at a 40% to 60% discount.

Learn more and become a member

comments powered by Disqus